239 related articles for article (PubMed ID: 22782312)
21. Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy.
Sabet A; Ezziddin S; Heinemann F; Guhlke S; Muckle M; Willinek W; Biersack HJ; Ahmadzadehfar H
Nuklearmedizin; 2012; 51(3):95-100. PubMed ID: 22421930
[TBL] [Abstract][Full Text] [Related]
22. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
23. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
[TBL] [Abstract][Full Text] [Related]
24. Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate.
de Keizer B; van Aken MO; Feelders RA; de Herder WW; Kam BL; van Essen M; Krenning EP; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):749-55. PubMed ID: 18210106
[TBL] [Abstract][Full Text] [Related]
25. Super-selective hepatic arterial infusions as established technique ('ARETAIEION' Protocol) of [177Lu]DOTA-TATE in inoperable neuroendocrine liver metastases of gastro-entero-pancreatic (GEP) tumors.
Limouris GS; Karfis I; Chatzioannou A; Paphiti MI; Lyra M; Gennatas K; Nikou G; Voros D; Pragulidis GP; Polydorou AA; Gouliamos A
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):551-8. PubMed ID: 23358409
[TBL] [Abstract][Full Text] [Related]
26. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.
van Vliet EI; van Eijck CH; de Krijger RR; Nieveen van Dijkum EJ; Teunissen JJ; Kam BL; de Herder WW; Feelders RA; Bonsing BA; Brabander T; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2015 Nov; 56(11):1647-53. PubMed ID: 26272813
[TBL] [Abstract][Full Text] [Related]
28. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
[TBL] [Abstract][Full Text] [Related]
30. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
31. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.
Krenning EP; Valkema R; Kwekkeboom DJ; de Herder WW; van Eijck CH; de Jong M; Pauwels S; Reubi JC
J Nucl Med; 2005 Jan; 46 Suppl 1():76S-82S. PubMed ID: 15653655
[TBL] [Abstract][Full Text] [Related]
32. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
[TBL] [Abstract][Full Text] [Related]
33. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
[TBL] [Abstract][Full Text] [Related]
34. Lutetium oxodotreotide (
Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
[TBL] [Abstract][Full Text] [Related]
35. The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE.
Wetz C; Genseke P; Apostolova I; Furth C; Ghazzawi S; Rogasch JMM; Schatka I; Kreissl MC; Hofheinz F; Grosser OS; Amthauer H
PLoS One; 2019; 14(5):e0216781. PubMed ID: 31091247
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
37. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate.
Kwekkeboom DJ; Bakker WH; Kam BL; Teunissen JJ; Kooij PP; de Herder WW; Feelders RA; van Eijck CH; de Jong M; Srinivasan A; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):417-22. PubMed ID: 12634971
[TBL] [Abstract][Full Text] [Related]
38. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
39. Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with
Adnan A; Basu S
J Nucl Med Technol; 2020 Mar; 48(1):36-39. PubMed ID: 31401619
[TBL] [Abstract][Full Text] [Related]
40. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
